drugset / Trial / NCT00532714
Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the response rate of capecitabine and irinotecan combination therapy in patients with metastatic breast cancer
Timeline
- Start
- 2006-08
- Primary completion
- 2008-04
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Comparator | Irinotecan | Small molecule | 80 mg/m2 | Intravenous |